Skinhealth Systems Inc.: what the price is pricing in

The price implies cash-flow growth of 2.3% a year; our model expects 2.0%. The gap is too narrow for a position this quarter. Switch lens below to see the same question asked of earnings, growth, sales and book value.

No published rating for Skinhealth Systems Inc.: held for review: our cash-flow value ($0.59) was left out of our combined valuation (it is 0.06x the share price, outside the 0.2-5x range we accept), so it can't be the basis of a rating. The readings below run our models backwards for research and show how trading the gap would have done; they are not a valuation or a rating. The valuation page shows the models and their status.

What growth in cash flow is the price paying for?

The price implies cash-flow growth of 2.3% a year; our model expects 2.0%.

Gap too narrow for a position this quarter

What the price implies What our model expects

Quarters with a position10 long, 1 short, since December 31, 2025

Beat the S&P 5000 of 10.0% of quarters held

Strategy against the index−100.0%cumulative; worst fall -100.0%

Over time

The growth in owner earnings (free cash flow after stock-based pay) that would justify the share price in our discounted-cash-flow model, against the growth the model itself assumes from the company's record.

Growth our model assumes Growth the price implies Long quarter Short quarter. Lower panel: the share price at each quarter end, adjusted for later share splits and spin-offs (the table below gives the price as traded).

Skill or luck?

In plain English: With only 1 quarters of positions, Skinhealth Systems Inc.'s own record is too short to tell skill from luck. The results across all companies on the priced-in page are the better guide.

Positions	Quarters	Beat the S&P 500	Average vs S&P 500, a quarter	Typical (median), a quarter	A year	Confidence (t)	Evidence
Longs	0	—	—	—	—	—	—
Shorts	1	0.0%	−1184.9%	−1184.9%	—	—	Too few quarters
All positions	1	0.0%	−1184.9%	−1184.9%	—	—	Too few quarters

Each position is measured against the S&P 500 over the same quarter: a long earns the stock's return minus the index's, a short the index's minus the stock's. "A year" compounds the per-quarter results. Evidence: strong at a t-statistic of 2 or more, some from 1.5; "worse" when the result is that far below zero; one company's history is a small sample, so read these alongside the results across all companies.

Every quarter (4)

From	Price paid	Growth the price implies	Growth our model assumes	Position	SKIN	S&P 500
September 30, 2026 (open)	$0.63	2.3%	2.0%	No position	−17.6%	−0.8%
June 30, 2026	$0.69	-0.2%	2.0%	No position	−9.1%	+2.4%
March 31, 2026	$0.89	7.3%	4.0%	No position	−22.1%	+15.1%
December 31, 2025	$0.07	18.2%	4.0%	Short	+1180.6%	−4.4%

Price paid: the closing price that day as traded, before any later share split.

What growth in earnings is the price paying for?

No current reading. The latest is from March 31, 2023: the figures this lens needs have not been filed recently enough (or no longer apply), so there is no position this quarter.

Quarters with a position11 long, 0 short, since March 31, 2023

Beat the S&P 5000 of 10.0% of quarters held

Strategy against the index−42.4%cumulative; worst fall -42.4%

Over time

The earnings growth the price-to-earnings ratio requires, against the growth our model assumes. Net income is already after interest, so it is valued at the return shareholders require, plus spare cash (none for banks and insurers, whose cash is funded by deposits and policies), with no debt subtracted.

Growth our model assumes Growth the P/E implies Long quarter Short quarter. Lower panel: the share price at each quarter end, adjusted for later share splits and spin-offs (the table below gives the price as traded).

Skill or luck?

Positions	Quarters	Beat the S&P 500	Average vs S&P 500, a quarter	Typical (median), a quarter	A year	Confidence (t)	Evidence
Longs	1	0.0%	−42.4%	−42.4%	−89.0%	—	Too few quarters
Shorts	0	—	—	—	—	—	—
All positions	1	0.0%	−42.4%	−42.4%	−89.0%	—	Too few quarters

Every quarter (1)

From	Price paid	Growth the P/E implies	Growth our model assumes	Position	SKIN	S&P 500
March 31, 2023	$0.63	-30.0%*	13.0%	Long	−33.7%	+8.7%

Price paid: the closing price that day as traded, before any later share split. * At the edge of the range we solve for.

What profit margin is the price paying for?

The price implies an owner-earnings margin of 4.6%; the company has kept 4.5%.

Gap too narrow for a position this quarter

What the price implies What the company delivered

Quarters with a position110 long, 11 short, since March 31, 2023

Beat the S&P 5008 of 1172.7% of quarters held

Strategy against the index+291.7%cumulative; worst fall -32.4%

$10,000 became$76,182S&P 500 bought and held: $19,457

Over time

The owner-earnings margin (free cash flow after stock pay, as a share of revenue) the price requires at our model's growth, against the margin the company has delivered over three years.

Margin delivered Margin the price implies Long quarter Short quarter. Lower panel: the share price at each quarter end, adjusted for later share splits and spin-offs (the table below gives the price as traded).

$10,000 trading the gap vs the S&P 500

StrategyS&P 500, buy and hold Hypothetical, before costs. The strategy holds the S&P 500 and only changes on a signal: it switches into SKIN in long quarters and adds a short of SKIN in short quarters. The gap between the lines is what the signal added or lost.

Skill or luck?

In plain English: Across 11 quarters with a position, this lens beat the S&P 500 in 8, by +17.8% a quarter on average. That is suggestive but could still be chance. One company is a small sample: the results across all companies are the better guide.

Positions	Quarters	Beat the S&P 500	Average vs S&P 500, a quarter	Typical (median), a quarter	A year	Confidence (t)	Evidence
Longs	0	—	—	—	—	—	—
Shorts	11	72.7%	+17.8%	+24.9%	+64.3%	1.81	Some evidence
All positions	11	72.7%	+17.8%	+24.9%	+64.3%	1.81	Some evidence

Every quarter (15)

From	Price paid	Margin the price implies	Margin delivered	Position	SKIN	S&P 500
September 30, 2026 (open)	$0.63	4.6%	4.5%	No position	−17.6%	−0.8%
June 30, 2026	$0.69	4.7%	5.3%	No position	−9.1%	+2.4%
March 31, 2026	$0.89	4.8%	3.9%	No position	−22.1%	+15.1%
December 31, 2025	$0.07	2.7%	1.2%	No position	+1180.6%	−4.4%
September 30, 2025	$0.10	2.9%	-3.7%	Short	−30.1%	+2.7%
June 30, 2025	$0.10	3.2%	-7.8%	Short	+4.2%	+8.1%
March 31, 2025	$0.07	3.1%	-12.1%	Short	+42.5%	+10.8%
December 31, 2024	$0.08	3.1%	-13.6%	Short	−15.7%	−4.3%
September 30, 2024	$0.07	2.5%	-14.4%	Short	+10.4%	+2.5%
June 30, 2024	$0.10	1.9%	-18.4%	Short	−25.0%	+5.8%
March 31, 2024	$0.22	2.5%	-16.7%	Short	−56.8%	+4.4%
December 31, 2023	$0.16	1.4%	-18.2%	Short	+42.8%	+10.4%
September 30, 2023	$0.30	1.3%	-20.7%	Short	−48.3%	+11.6%
June 30, 2023	$0.42	1.5%	-28.8%	Short	−28.1%	−3.2%
March 31, 2023	$0.63	2.2%	-28.9%	Short	−33.7%	+8.7%

Price paid: the closing price that day as traded, before any later share split.

What return on equity is the price paying for?

The price implies a return on equity of 11.3%; the company earned -43.9%.

Market more optimistic than our model: short this quarter

What the price implies What the company delivered

Quarters with a position141 long, 13 short, since March 31, 2023

Beat the S&P 5009 of 1464.3% of quarters held

Strategy against the index−100.0%cumulative; worst fall -100.0%

$10,000 became$0S&P 500 bought and held: $19,457

Over time

The return on equity that justifies the price-to-book ratio, (P/B)(r − g) + g with an 8.5% required return and 2.5% long-run growth, against the return the company delivered last year.

Return on equity delivered Return on equity the price implies Long quarter Short quarter. Lower panel: the share price at each quarter end, adjusted for later share splits and spin-offs (the table below gives the price as traded).

$10,000 trading the gap vs the S&P 500

Skill or luck?

In plain English: Across 14 quarters with a position, this lens beat the S&P 500 in 9, by −73.3% a quarter on average. That could easily be chance. One company is a small sample: the results across all companies are the better guide.

Positions	Quarters	Beat the S&P 500	Average vs S&P 500, a quarter	Typical (median), a quarter	A year	Confidence (t)	Evidence
Longs	1	0.0%	−42.4%	−42.4%	−89.0%	—	Too few quarters
Shorts	13	69.2%	−75.6%	+11.5%	—	-0.82	No reliable evidence
All positions	14	64.3%	−73.3%	+11.5%	—	-0.85	No reliable evidence

Every quarter (15)

From	Price paid	Return on equity the price implies	Return on equity delivered	Position	SKIN	S&P 500
September 30, 2026 (open)	$0.63	11.3%	-43.9%	Short	−17.6%	−0.8%
June 30, 2026	$0.69	12.4%	-11.9%	Short	−9.1%	+2.4%
March 31, 2026	$0.89	15.7%	-16.9%	Short	−22.1%	+15.1%
December 31, 2025	$0.07	3.3%	-18.7%	Short	+1180.6%	−4.4%
September 30, 2025	$0.10	3.6%	-26.5%	Short	−30.1%	+2.7%
June 30, 2025	$0.10	4.1%	-70.4%	Short	+4.2%	+8.1%
March 31, 2025	$0.07	3.7%	-52.3%	Short	+42.5%	+10.8%
December 31, 2024	$0.08	3.5%	-37.6%	Short	−15.7%	−4.3%
September 30, 2024	$0.07	3.4%	-72.5%	Short	+10.4%	+2.5%
June 30, 2024	$0.10	3.8%	-74.7%	Short	−25.0%	+5.8%
March 31, 2024	$0.22	5.4%	-88.4%	Short	−56.8%	+4.4%
December 31, 2023	$0.16	3.9%	-49.4%	Short	+42.8%	+10.4%
September 30, 2023	$0.30	4.0%	-4.1%	Short	−48.3%	+11.6%
June 30, 2023	$0.42	4.7%	-3.1%	Short	−28.1%	−3.2%
March 31, 2023	$0.63	5.6%	19.0%	Long	−33.7%	+8.7%

Price paid: the closing price that day as traded, before any later share split.

How the test works

At each quarter end since March 2010 we rebuild the models from Skinhealth Systems Inc.'s quarters ending at least 90 days earlier (and no more than 200 days before that), using the figures as later filed, including any restatement, and value them at that day's close, adjusted for later share splits and spin-offs so that price and share count are on the same basis. A wide enough gap is a long or a short for one quarter (growth 10 points; margin and return on equity 5 points; a PEG under 0.75 or over 3), measured on total return against the S&P 500. The rules were set before the test. No trading or borrowing costs; today's list of companies. Not investment advice. All companies and the results across them.

Compare with peers

Head to head: AXGN vs SKIN KIDS vs SKIN LMAT vs SKIN

More: Health Care Equipment stocks compared, Health Care sector, rankings of US companies

Figures from Skinhealth Systems Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Skinhealth Systems Inc.